Drug intelligence / Profile preview

BG-C137

Development stage: Phase 1
Lead developer: BeOne Medicines
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BG-C137 is an investigational anti-FGFR2b antibody-drug conjugate (ADC) developed by BeiGene for the treatment of advanced solid tumors. The drug is designed to selectively target and bind to the Fibroblast growth factor receptor 2b (FGFR2b) isoform, a member of the fibroblast growth factor receptor family that is implicated in tumor growth and progression. Upon binding, the ADC delivers a cytotoxic payload directly to cancer cells expressing FGFR2b, aiming to enhance antitumor activity while minimizing off-target effects. BG-C137 is currently being evaluated in Phase 1 clinical trials for safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy in patients with advanced solid tumors.

Other names: EGFR×FGFR2b bispecific antibody-drug conjugateEGFR/FGFR2b bispecific ADCEGFR x FGFR2b bsADC

Targets

FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)

Beyond the preview

Go deeper on BG-C137.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BG-C137.

Explore the full profile